PMID- 35321472
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220325
IS  - 2296-858X (Print)
IS  - 2296-858X (Electronic)
IS  - 2296-858X (Linking)
VI  - 9
DP  - 2022
TI  - Plasma Homocysteine as a Potential Marker of Early Renal Function Decline in IgA 
      Nephropathy.
PG  - 812552
LID - 10.3389/fmed.2022.812552 [doi]
LID - 812552
AB  - Hyperhomocysteinemia (HHcy) is very common among patients with chronic kidney 
      disease (CKD), and related to the risk of cardiovascular events and mortality in 
      these patients. However, the prevalence of HHcy in primary causes of CKD and its 
      role in kidney disease progression are not well-understood. In this study, we 
      investigated the prevalence of HHcy in different CKD stages in 221 patients with 
      IgA nephropathy (IgAN) and 194 patients with other primary glomerular diseases. 
      We also evaluated the association of homocysteine (Hcy) [after adjusted for 
      estimated glomerular filtration rate (eGFR)] with CKD progression event, defined 
      as ESKD or 50% decline in eGFR, in a cohort of 365 patients with IgAN. The 
      prevalence of HHcy was 67.9% (150/221), 53.5% (76/142), 51.5% (17/33), and 42.1% 
      (8/19) in patients with IgAN, membranous nephropathy, minimal change disease, 
      focal segmental glomerulosclerosis, respectively. The Hcy/eGFR ratio was 
      significantly associated with pathologic features of IgAN, including the 
      proportion of global glomerulosclerosis (r = 0.38, p < 0.001), the proportion of 
      ischemia originated glomerular sclerosis (r = 0.32, p < 0.001), and the severity 
      of tubular atrophy/interstitial fibrosis (r = 0.57, p < 0.001). Importantly, 
      Hcy/eGFR ratio was an independent risk factor for CKD progression event (hazard 
      ratio, 1.38; 95% confidence interval, 1.13-1.68; p = 0.002). The risk of CKD 
      progression events continuously increased with the Hcy/eGFR ratio, but reached a 
      plateau when Hcy/eGFR ratio was >1.79. Our findings suggest that elevated 
      Hcy/eGFR ratio may be an early marker of poor renal outcome in IgAN.
CI  - Copyright (c) 2022 Wang, Xia, Song, Zhou and Zhang.
FAU - Wang, Yan-Na
AU  - Wang YN
AD  - Renal Division, Peking University First Hospital, Beijing, China.
AD  - Peking University Institute of Nephrology, Beijing, China.
AD  - Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, China.
AD  - Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking 
      University), Ministry of Education, Beijing, China.
FAU - Xia, Han
AU  - Xia H
AD  - Renal Division, Xingtai City People's Hospital, Xingtai, China.
FAU - Song, Zhuo-Ran
AU  - Song ZR
AD  - Renal Division, Peking University First Hospital, Beijing, China.
AD  - Peking University Institute of Nephrology, Beijing, China.
AD  - Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, China.
AD  - Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking 
      University), Ministry of Education, Beijing, China.
FAU - Zhou, Xu-Jie
AU  - Zhou XJ
AD  - Renal Division, Peking University First Hospital, Beijing, China.
AD  - Peking University Institute of Nephrology, Beijing, China.
AD  - Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, China.
AD  - Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking 
      University), Ministry of Education, Beijing, China.
FAU - Zhang, Hong
AU  - Zhang H
AD  - Renal Division, Peking University First Hospital, Beijing, China.
AD  - Peking University Institute of Nephrology, Beijing, China.
AD  - Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, China.
AD  - Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking 
      University), Ministry of Education, Beijing, China.
LA  - eng
PT  - Journal Article
DEP - 20220307
PL  - Switzerland
TA  - Front Med (Lausanne)
JT  - Frontiers in medicine
JID - 101648047
PMC - PMC8936167
OTO - NOTNLM
OT  - IgA nephropathy
OT  - chronic kidney disease
OT  - homocysteine
OT  - kidney disease progression
OT  - primary glomerular diseases
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/03/25 06:00
MHDA- 2022/03/25 06:01
PMCR- 2022/03/07
CRDT- 2022/03/24 05:15
PHST- 2021/11/10 00:00 [received]
PHST- 2022/02/14 00:00 [accepted]
PHST- 2022/03/24 05:15 [entrez]
PHST- 2022/03/25 06:00 [pubmed]
PHST- 2022/03/25 06:01 [medline]
PHST- 2022/03/07 00:00 [pmc-release]
AID - 10.3389/fmed.2022.812552 [doi]
PST - epublish
SO  - Front Med (Lausanne). 2022 Mar 7;9:812552. doi: 10.3389/fmed.2022.812552. 
      eCollection 2022.